How many drugs treat Blepharoconjunctivitis?

Drug Landscape tracks 10 marketed treatments for Blepharoconjunctivitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/blepharoconjunctivitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Blepharoconjunctivitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blepharoconjunctivitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Blepharoconjunctivitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Trimethoprim	TRIMETHOPRIM	Dr Reddys Labs Sa	Sulfonamide Antimicrobial [EPC]	Dihydrofolate reductase	1973-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Gramoderm	GRAMICIDIN	Pfizer	gramicidin	Thromboxane-A synthase	1968-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Cortisporin	NEOMYCIN	Pfizer	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 1	1957-01-01
Cortisporin	POLYMYXIN B	Pfizer	Polymyxin-class Antibacterial		1957-01-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 6 drugs in Blepharoconjunctivitis
Merck & Co. · 3 drugs in Blepharoconjunctivitis
· 2 drugs in Blepharoconjunctivitis
Generic (originally Merck/Upjohn) · 1 drug in Blepharoconjunctivitis
Generic (originally Schering) · 1 drug in Blepharoconjunctivitis
Hannover Medical School · 1 drug in Blepharoconjunctivitis
Novartis · 1 drug in Blepharoconjunctivitis
University Hospital, Lille · 1 drug in Blepharoconjunctivitis
University of Zurich · 1 drug in Blepharoconjunctivitis
Dr Reddys Labs Sa · 1 drug in Blepharoconjunctivitis
Generic (originally Merck) · 1 drug in Blepharoconjunctivitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Blepharoconjunctivitis:

Cite this brief

Drug Landscape (2026). Blepharoconjunctivitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/blepharoconjunctivitis. Accessed 2026-06-10.

Blepharoconjunctivitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing